Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines (Q43411752)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 April 2012

Language	Label	Description	Also known as
English	Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines	scientific article published on 29 April 2012

Statements

scholarly article

1 reference

Europe PubMed Central

23 November 2017

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines (English)

1 reference

Europe PubMed Central

23 November 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

Annett Mueller

1

1 reference

Europe PubMed Central

23 November 2017

Erika Bachmann

2

1 reference

Europe PubMed Central

23 November 2017

Monika Linnig

3

1 reference

Europe PubMed Central

23 November 2017

Katrin Khillimberger

4

1 reference

Europe PubMed Central

23 November 2017

Carl Christoph Schimanski

5

1 reference

Europe PubMed Central

23 November 2017

Peter R Galle

6

1 reference

Europe PubMed Central

23 November 2017

Markus Moehler

7

1 reference

Europe PubMed Central

23 November 2017

publication date

29 April 2012

1 reference

Europe PubMed Central

23 November 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

23 November 2017

69

1 reference

Europe PubMed Central

23 November 2017

6

1 reference

Europe PubMed Central

23 November 2017

1601-1615

1 reference

Europe PubMed Central

23 November 2017

https://scigraph.springernature.com/pub.10.1007/s00280-012-1869-z

0 references

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

AKT/PKB signaling: navigating downstream

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The prevalence of PIK3CA mutations in gastric and colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The applicability of mTOR inhibition in solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Mutations of PIK3CA in gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Oncogenic mutations in gastric cancer with microsatellite instability.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

NVP-BEZ235 as a new therapeutic option for sarcomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

The life of a cell: apoptosis regulation by the PI3K/PKB pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Status of PI3K inhibition and biomarker development in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1869-Z

21 January 2018

Identifiers

10.1007/S00280-012-1869-Z

1 reference

Europe PubMed Central

23 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43411752&oldid=1988260481"